-
Mashup Score: 4The Art of Immunotherapy - 4 month(s) ago
Selection of a patient with rhinitis/conjunctivitis or asthma for allergy immunotherapy (AIT) requires several decisions. First, does the patient’s sensitization, pattern of exposure to an allergen, and degree of exposure to that allergen reasonably suggest a causal relationship? Does the level and duration of symptoms warrant the cost and inconvenience of immunotherapy, or is the patient motivated by the disease-modifying potential of AIT? If AIT is selected, is the choice to be greater safety and convenience with sublingual immunotherapy (SLIT) tablets, but with treatment probably limited to 2 or 3 allergens, or for subcutaneous immunotherapy where multiple allergen therapy is the rule and efficacy may be somewhat greater, at least initially, or does the physician go off-label into the unknowns of liquid SLIT? Are there extracts of sufficient potency to achieve likely effective doses? How does the physician deal with large local or systemic reactions, with gaps in treatment, with pol
Source: www.jaci-inpractice.orgCategories: General Medicine News, Allergy-ImmunologyTweet
-
Mashup Score: 2Courtney | Leukemia and Lymphoma Society - 4 month(s) ago
In March 2022, I began experiencing unusual symptoms of fatigue, nausea, persistent infections, and bloody noses and gums, but I didn’t think much of it. Following a lucky-timed appointment with my primary care doctor and multiple blood tests, I was diagnosed with acute lymphoblastic leukemia (ALL). Cancer isn’t something an otherwise “healthy” 27-year-old thinks will come out of a doctor’s mouth. Just hours after I first heard the “c-word,” I was admitted inpatient to a cancer center, and just two days later, I began chemotherapy. My initial treatment plan consisted of eight rounds of high-intensity chemotherapy, 12 intrathecal chemotherapy lumbar punctures, oral targeted therapy, and further down the line a stem cell transplant. The chemotherapy rounds dragged on, they were severe, brutal, and isolating. Following three rounds of chemotherapy, I was determined that there had to be another way and sought out a second opinion. Thanks to the dedication of some amazing, daring medical pr
Source: www.lls.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 11HOME - Advances in Cancer Vaccines - 6 month(s) ago
Join me at this event!
Source: conferences.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 15Allogenic Blood-Derived Natural Killer Cells in Cancer Refractory to Conventional Therapy - 6 month(s) ago
The purpose of this study is to evaluate a blood-derived experimental therapy in patients who have refractory cancer that has failed conventional,
Source: clinicaltrials.cedars-sinai.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 65Multivalent, asymmetric IL-2–Fc fusions show enhanced selectivity for regulatory T cells - 6 month(s) ago
Engineering an α chain–biased, multivalent IL-2 may improve its utility in treating autoimmunity.
Source: www.science.orgCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 64Multivalent, asymmetric IL-2–Fc fusions show enhanced selectivity for regulatory T cells - 7 month(s) ago
Engineering an α chain–biased, multivalent IL-2 may improve its utility in treating autoimmunity.
Source: www.science.orgCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 0Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study - 7 month(s) ago
Specific components of lipid profile have different effects on immune activity against cancer. This study aimed to unravel their prognostic role in solid tumors
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0FDA Approves Neoadjuvant/Adjuvant Pembrolizumab for Resectable NSCLC - The ASCO Post - 7 month(s) ago
On October 16, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent pembrolizumab as postsurgical adjuvant treatment, for resectable (tumors ≥ 4 cm or node-positive) non–small cell lung cancer (NSCLC). Efficacy was evaluated in KEYNOTE-671 (ClinicalTrials.gov identifier NCT03425643), a multicenter, randomized, double-blind, pla cebo-controlled trial in 797 patients with previously
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 9Re-activating the immune system against cancer: The next I-O revolution - Endpoints Webinars - 7 month(s) ago
Patients dealing with cancers that have resisted immuno-oncology (IO) therapies potentially have a new treatment option on the horizon. More than a decade after the first checkpoint inhibitor raised hopes, next-generation investigational IO is lighting up clinics with long-sought encouraging results against the persistent “cold” tumors involved in colorectal, lung,
Source: webinars.endpts.comCategories: Hem/Oncs, Latest HeadlinesTweet-
I’m so excited & honored. Still time to register for the webinar at @endpts today at 1 pm🕐EST. If there’s a class of drugs that I’m most excited about for my patients, it is #immunotherapy. Open to all: patients, caregivers, advocates, industry. Link: https://t.co/XtkoxJNPAw https://t.co/PHNYmJzYQO https://t.co/TztquyHp6R
-
-
Mashup Score: 3
PURPOSE Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC). METHODS This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or second-/third-line (2L/3L) treatment (arm F). The primary end point of dose expansion was objective response rate (ORR). RESULTS A total of 142 patients were enrolled. In dose escalation (n = 41), no DLTs were observ
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
In Current Issue! The Art of #Immunotherapy https://t.co/aQGbViyY5S https://t.co/ilMiHrkeII